News

/News

Metrion Biosciences closes funding round

2019-04-01T08:22:36+00:00

Metrion Biosciences Closes Funding Round Includes investment from o2h Ventures Therapeutics Fund Funding to support expansion of ion channel screening capabilities and continued research into potential drugs for auto-immune diseases Cambridge, UK, 01 April 2019: Metrion Biosciences Ltd (“Metrion”), the specialist ion channel contract research and drug discovery company, announced today that it has completed [...]

Metrion Biosciences closes funding round2019-04-01T08:22:36+00:00

Metrion awarded £637k Innovate UK Biomedical Catalyst primer award

2018-09-10T14:40:22+00:00

Metrion Biosciences awarded £637k funding under Innovate UK Biomedical Catalyst Primer Award for ion channel drug discovery • Funding will support project aiming to identify novel oral therapeutics for the auto-immune disease psoriasis • Adds to Innovate UK funding awarded in February 2018 for research on potassium channel inhibitors Cambridge, UK, 28 August 2018: Metrion [...]

Metrion awarded £637k Innovate UK Biomedical Catalyst primer award2018-09-10T14:40:22+00:00

Metrion appoints two new Board Directors

2018-08-01T14:30:28+00:00

Dr Barry Kenny joins as Non-Executive Director Dr Andrew Southan, COO, appointed Executive Director Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced it has appointed Dr Barry Kenny and Dr Andrew Southan to its Board of Directors. The appointments have been made to strengthen the Company’s focus [...]

Metrion appoints two new Board Directors2018-08-01T14:30:28+00:00

Metrion Biosciences establishes Scientific Advisory Board

2018-11-26T15:28:23+00:00

Scientific Advisory Board will provide scientific oversight and strategic advice to support Metrion’s ion channel screening, cardiac safety testing, and native tissue and human stem cell translational assays. Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced that it has established a Science Advisory Board (SAB) to provide [...]

Metrion Biosciences establishes Scientific Advisory Board2018-11-26T15:28:23+00:00

Innovate UK Biomedical Catalyst Feasibility Award

2018-07-18T16:02:11+00:00

Metrion Biosciences awarded £200k funding under Innovate UK Biomedical Catalyst Feasibility Award Funding will support further development of recently acquired small molecule assets for treatment of autoimmune disease Project forms the first of a series designed to deliver proof of concept data on immune-sparing drug candidates Project will further enhance Metrion’s ion channel drug discovery [...]

Innovate UK Biomedical Catalyst Feasibility Award2018-07-18T16:02:11+00:00

Novel potassium channel inhibitors acquired from Japan Tobacco Inc.

2018-04-13T13:35:54+00:00

Acquired intellectual property rights have potential application in a variety of clinical indications, including auto-immune disorders and neurodegenerative diseases. Metrion now owns all patented and unpatented IP developed during previous collaboration between Metrion and Japan Tobacco Inc. Cambridge, UK, 29 January 2018: Metrion Biosciences Ltd (“Metrion”), the specialist ion channel contract research and drug discovery [...]

Novel potassium channel inhibitors acquired from Japan Tobacco Inc.2018-04-13T13:35:54+00:00

Metrion collaborates with Candidate Biopharma Advisors

2018-09-10T15:12:23+00:00

Metrion Biosciences today announced a collaboration with Chris Mathes PhD, founder of Candidate Biopharma Advisors, to broaden Metrion's exposure in the North American market. Chris is well qualified to promote Metrion's excellence in ion channel drug discovery, safety profiling and translational assays. Like the majority of our staff, he started his career as a conventional [...]

Metrion collaborates with Candidate Biopharma Advisors2018-09-10T15:12:23+00:00

Metrion Biosciences opens SyndicateRoom investment round

2018-03-09T15:53:46+00:00

Cambridge, UK, 16 January 2018: Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, and online investment platform SyndicateRoom, announced today the opening of a £600k investment round in Metrion. Metrion will use the funds to expand its rapidly growing fee-for-service business. This is the first private investment round for [...]

Metrion Biosciences opens SyndicateRoom investment round2018-03-09T15:53:46+00:00

Metrion Biosciences 2017 review

2018-01-12T11:36:06+00:00

Thanks to our Customers: the Metrion Biosciences team would like to thank our customers for placing business with us in 2017. We take great pride in providing a high-quality service to advance early stage drug discovery research for our clients, whether it be integrated drug discovery, new target screening, stand-alone safety profiling and/or translational assay [...]

Metrion Biosciences 2017 review2018-01-12T11:36:06+00:00

Metrion Biosciences announce collaboration with LifeArc

2019-08-08T16:14:06+00:00

LifeArc and Metrion Biosciences extend partnership agreement to support LifeArc's neuroscience small molecule drug discovery programme. Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, the UK medical research charity previously known as MRC Technology, today announced an extension of  their existing partnership, to support LifeArc’s neuroscience drug discovery [...]

Metrion Biosciences announce collaboration with LifeArc2019-08-08T16:14:06+00:00